Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | ChemoCentryx, Inc. CCXI |
RA CAPITAL MANAGEMENT L.P. | 4,776,548 6.900% |
1,577,159 (+49.30%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | ARYA SCIENCES ACQUISITION CORP ARYA |
RA CAPITAL MANAGEMENT L.P. | 1,000,000 6.700% |
1,000,000 (New Position) |
Filing History |
| 2021-02-16 4:39 pm Sale |
2020-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
RA CAPITAL MANAGEMENT L.P. | 564,102 1.700% |
-1,311,107 (-69.92%) |
Filing History |
| 2021-02-16 4:39 pm Sale |
2020-12-31 | 13G | Vaxcyte, Inc. PCVX |
RA CAPITAL MANAGEMENT L.P. | 3,710,699 7.300% |
-1,778,482 (-32.40%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Phathom Pharmaceuticals, Inc. PHAT |
RA CAPITAL MANAGEMENT L.P. | 3,825,008 12.300% |
178,200 (+4.89%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | Zogenix, Inc. ZGNX |
RA CAPITAL MANAGEMENT L.P. | 5,345,631 9.600% |
3,084,880 (+136.45%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | scPharmaceuticals Inc. SCPH |
RA CAPITAL MANAGEMENT L.P. | 3,518,998 12.900% |
271,993 (+8.38%) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | BCLS Acquisition Corp. BLSA |
RA CAPITAL MANAGEMENT L.P. | 1,250,000 8.400% |
1,250,000 (New Position) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | 5:01 Acquisition Corp. FVAM |
RA CAPITAL MANAGEMENT L.P. | 750,000 8.700% |
750,000 (New Position) |
Filing History |
| 2021-02-16 4:39 pm Purchase |
2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY |
RA CAPITAL MANAGEMENT L.P. | 1,742,186 5.000% |
1,742,186 (New Position) |
Filing History |
| 2021-02-16 4:34 pm Purchase |
2020-12-31 | 13G | Verona Pharma plc VRNA |
RA CAPITAL MANAGEMENT L.P. | 41,543,004 9.990% |
41,543,004 (New Position) |
Filing History |
| 2021-02-11 4:46 pm Sale |
2021-02-09 | 13G | Iterum Therapeutics plc ITRM |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-915,358 (Position Closed) |
Filing History |
| 2021-02-10 4:49 pm Sale |
2021-01-31 | 13G | TG Therapeutics, Inc. TGTX |
RA CAPITAL MANAGEMENT L.P. | 6,361,123 4.700% |
-6,427,334 (-50.26%) |
Filing History |
| 2021-02-10 4:48 pm Sale |
2021-01-31 | 13G | Keros Therapeutics, Inc. KROS |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-1,875,000 (Position Closed) |
Filing History |
| 2021-02-10 4:47 pm Sale |
2021-01-31 | 13G | Arvinas, Inc. ARVN |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-3,672,872 (Position Closed) |
Filing History |
| 2021-02-10 4:46 pm Sale |
2021-01-31 | 13G | Cardiff Oncology, Inc. CRDF |
RA CAPITAL MANAGEMENT L.P. | 0 0.000% |
-3,290,000 (Position Closed) |
Filing History |
| 2021-02-10 4:34 pm Purchase |
2020-12-31 | 13G | Eiger BioPharmaceuticals, Inc. EIGR |
RA CAPITAL MANAGEMENT L.P. | 289,516 6.400% |
289,516 (New Position) |
Filing History |
| 2021-02-10 4:31 pm Purchase |
2020-12-31 | 13G | Keros Therapeutics, Inc. KROS |
RA CAPITAL MANAGEMENT L.P. | 1,875,000 8.100% |
1,875,000 (New Position) |
Filing History |
| 2021-02-08 5:16 pm Purchase |
2021-02-04 | 13G | Iterum Therapeutics plc ITRM |
RA CAPITAL MANAGEMENT L.P. | 915,358 10.600% |
248,692 (+37.30%) |
Filing History |
| 2021-01-29 4:30 pm Purchase |
2021-01-29 | 13G | CytomX Therapeutics, Inc. CTMX |
RA CAPITAL MANAGEMENT L.P. | 3,500,000 5.800% |
3,500,000 (New Position) |
Filing History |